• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Investigating Fungi-Derived Bioactive Molecules as Inhibitor of the SARS Coronavirus Papain Like Protease: Computational Based Study
We presented the drug likeliness, toxicity, carcinogenicity, and mutagenicity of all compounds using ADMET analysis. They interacted with the amino acid residues, Gly163, Trp106, Ser111, Asp164, and Cys270, through hydrogen bonds. The root-mean-square deviation (RMSD), root-mean-square fluctuations (RMSF), solvent-accessible surface area (SASA), and radius of gyration (Rg) values revealed a stable interaction. From the overall analyses, we can conclude that Dihydroaltersolanol C, Anthraquinone, Nigbeauvin A, and Catechin are classified as promising candidates for PLpro, thus potentially useful in developing a medicine for ...
Source: Molecular Medicine - November 8, 2021 Category: Molecular Biology Authors: Aweke Mulu Belachew Asheber Feyisa Seid Belay Mohamed Jerusalem Fekadu W/Mariam Source Type: research

Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Biomed Pharmacother. 2021 Mar 16;138:111518. doi: 10.1016/j.biopha.2021.111518. Online ahead of print.ABSTRACTSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2020 and coronavirus disease 19 (COVID-19) was later announced as pandemic by the World Health Organization (WHO). Since then, several studies have been conducted on the prevention and treatment of COVID-19 by potential vaccines and drugs. Although, the governments and global population have been attracted by some vaccine production projects, the presence of SARS-CoV-2-specific antiviral drugs would be an urge necessit...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 28, 2021 Category: Drugs & Pharmacology Authors: Mona Sadat Mirtaleb Amir Hossein Mirtaleb Hassan Nosrati Jalal Heshmatnia Reza Falak Reza Zolfaghari Emameh Source Type: research

Resolution of coronavirus disease 2019 (COVID-19).
Authors: Habas K, Nganwuchu C, Shahzad F, Gopalan R, Haque M, Rahman S, Majumder AA, Nasim T Abstract INTRODUCTION: Coronavirus disease 2019 (COVID-19) was first detected in China in December, 2019, and declared as a pandemic by the World Health Organization (WHO) on March 11, 2020. The current management of COVID-19 is based generally on supportive therapy and treatment to prevent respiratory failure. The effective option of antiviral therapy and vaccination are currently under evaluation and development. AREAS COVERED: A literature search was performed using PubMed between December 1, 2019-June 23, 2020. This...
Source: Expert Review of Anti-Infective Therapy - August 13, 2020 Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research

Understanding and implementing alternative solutions to address the COVID-19 pandemic in the sense of public health emergencies.
Authors: Bhole RP, Sarode VI, Bonde CG Abstract The Coronavirus disease (COVID-19) caused by the novel SARS-CoV-2 coronavirus has spread from China and quickly transmitted to most other countries around the world. The World Health Organization announced COVID-19 as a pandemic that is spreading steadily and soon in most states. Coronavirus genomic characterization showed that it most closely resembled another bat-origin beta-coronavirus. Coronavirus has the largest genome of viruses that have RNA. Spike (S) glycoprotein is present in the virus and is responsible for virus entry into the host cell. COVID-19 can sprea...
Source: European Review for Medical and Pharmacological Sciences - July 28, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19.
Abstract As a rapidly developing etiology of a global disease, the -coronavirus family virion, SARS-CoV-2, has quickly evolved as a pandemic leading to coronavirus disease 2019 (COVID-19) and has been declared by the World Health Organization as a Public Health Emergency of International Concern. To date, no definitive treatment or vaccine application exists for COVID-19. Although new investigations seek to repurpose existing antiviral treatments for COVID-19, innovative treatment strategies not normally considered to have antiviral capabilities may be critical as well to address this global concern. One such a...
Source: Current Neurovascular Research - April 24, 2020 Category: Neurology Authors: Maiese K Tags: Curr Neurovasc Res Source Type: research

Antiviral therapy in management of COVID-19: a systematic review on current evidence.
Conclusion: The current evidence impede researchers from proposing an appropriate antiviral therapy against COVID-19, making the current situation a serious concern for international organizations such as World Health Organization (WHO). In the time of the current pandemic and future epidemics, organizations such as WHO should pursue more proactive actions and plan well-designed clinical trials so that their results can be used in managing future epidemics. PMID: 32309809 [PubMed]
Source: Accident and Emergency Nursing - April 21, 2020 Category: Emergency Medicine Authors: Yousefifard M, Zali A, Mohamed Ali K, Madani Neishaboori A, Zarghi A, Hosseini M, Safari S Tags: Arch Acad Emerg Med Source Type: research

A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization
Publication date: Available online 12 December 2017 Source:Antiviral Research Author(s): Renqiang Liu, Jinliang Wang, Yu Shao, Xijun Wang, Huilei Zhang, Lei Shuai, Jinying Ge, Zhiyuan Wen, Zhigao Bu Middle East respiratory syndrome coronavirus (MERS-CoV) has been a highly threatening zoonotic pathogen since its outbreak in 2012. Similar to SARS-CoV, MERS-CoV belongs to the coronavirus family and can induce severe respiratory symptoms in humans, with an average case fatality rate of 35% according to the World Health Organization. Spike (S) protein of MERS-CoV is immunogenic and can induce neutralizing antibodies, thus is a...
Source: Antiviral Therapy - December 13, 2017 Category: Virology Source Type: research